Gold-Backed Inflows Rise in Asia and Europe
In the past month, global gold-backed exchange traded fund holdings added 15 tonnes. Ultimately, Europe and Asia drove inflows.
All Work
Chris Lange
Why Axovant Shares More Than Doubled
Axovant Sciences shares more than doubled on Wednesday after the company announced a new licensing agreement.
Why Signet Jewelers’ Q1 Rocks
Signet Jewelers released better-than-expected fiscal first-quarter financial results before the markets opened on Wednesday.
Why Ambarella Shares Are Crumbling
Ambarella shares retreated early Wednesday after it released its fiscal first-quarter financial results late on Tuesday.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was a mixed day for the broad U.S. markets. The Nasdaq continued its streak and is closing at another record high. Crude oil stopped the bleeding somewhat with a slight gain on the…
Verrica Pharmaceuticals Closes in on IPO
Verrica Pharmaceuticals expects to price 5 million shares in the range that results in an initial public offering valued up to $92 million.
Wedbush’s Monday ASCO Roundup
The 54th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded and there were some significant moves we saw as a result.
Why Canaccord Genuity Is So Bullish on 2018
Canaccord Genuity has updated its Standard & Poor's 500 index target for 2018. What does the firm see for the second half of the year?
What’s Changed in the April JOLTS Report
The Bureau of Labor Statistics has issued its Job Openings and Labor Turnover Summary for the month of April.
Why Smartsheet Is Tuesday’s Big Earnings Winner
Smartsheet released better-than-expected fiscal first-quarter financial results after the markets closed on Monday.
How Deciphera Pharma Is Capitalizing Big on ASCO
Deciphera Pharmaceuticals saw its shares took a breather early Tuesday after the firm announced a secondary offering.
Mylan Wins Big With FDA Approval
Mylan saw its shares make a handy gain early on Tuesday after the FDA announced a key approval for Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim).
Monday’s Biggest Winners and Losers in the S&P 500
Monday was a solid day for the broad U.S. markets starting out the week with a gain. The Nasdaq closed at a record high, and for the first time above 7,600. Although, crude oil…
Consumers Finally Feeling Relief at the Pump
Oil prices continued their downward move from last week, paving the way for additional drops in gasoline prices in the near future.
Jounce Therapeutics Sinks on ASCO Update
Jounce Therapeutics watched its shares drop sharply on Monday after the company presented preliminary data from its early stage cancer trial at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Robots Take More Jobs at McDonald’s
McDonald's is solidifying a move to a more tech integrated platform according to its CEO. Essentially, the golden arches is making a big bet on mobile and other tech platforms, which would mean replacing…
Fitbit Ships Over 1 Million Versa Devices
Fitbit shares made a handy gain to start off the week after the company announced that it shipped more than a million Fitbit Versa devices since general availability began.
Why Nektar Therapeutics Shares Are Tumbling
Nektar Therapeutics (NASDAQ: NKTR) saw its shares get nearly halved in Monday’s session after the company released preliminary data from its early stage cancer study. The preliminary results presented at the 2018 American Society…
Microsoft Moves to Acquire GitHub
Microsoft saw its shares make a handy gain to start off the week after the firm announced that it would acquire GitHub.
Palo Alto Networks Hacks Its Way Back With Earnings
Palo Alto Networks released better-than-expected fiscal third-quarter financial results before the markets opened on Monday.